Skip to main content
SpringerLink
Log in

Use of Drugs that Affect Nutrition and Immune Function

  • Chapter
Diet and Human Immune Function

Part of the book series: Nutrition and Health ((NH))

Abstract

The objectives of this chapter are to examine the effects of drug treatments on four major immune-related diseases and to determine the nutritional consequences of the drug-disease interaction in adults living in developed countries. The diseases discussed include HIV infection, diabetes (type 1 and type 2), rheumatoid arthritis, and osteoporosis. Osteoporosis is included because of the role of the osteoclast, which is a macrophagederived cell involved in bone breakdown (1). Insulin is a significant enhancer of bone formation, and, therefore, osteoporosis is often a consequence of diabetes (2). Osteoporosis is also included after the discussion of rheumatoid arthritis (RA) because the major drug class used to treat RA, glucocorticoids, is a known cause of secondary osteoporosis (3–5). Finally, organ transplant-associated osteoporosis demonstrates the links between a medical event (transplantation), immunotherapy, and nutritional effects (6,7).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ershler WB, Harman SM, Keller ET. Immunologic aspects of osteoporosis. Dev Comp Immunol 1997;21:487–499.

    Article  PubMed  CAS  Google Scholar 

  2. Beers MH, Berkow R. Osteoporosis. In: Beers MH, Berkow R (eds.). The Merck Manual of Diagnosis and Therapy. Merck Research Laboratory, Whitehouse Station, NJ, 1999, pp. 469–473.

    Google Scholar 

  3. Bhattoa HP, Kiss E, Bettembuk P, Balogh A. Bone mineral density, biochemical markers of bone turnover, and hormonal status in men with systemic lupus erythematosus. Rheumatol Int 2001;21: 97–102.

    Article  PubMed  CAS  Google Scholar 

  4. Bikle DD. Osteoporosis in gastrointestinal, pancreatic, and hepatic diseases. In: Marcus R, Feldman D, Kelsey J (eds.). Osteoporosis (volume II). Academic Press, New York, 2001, pp. 237–258.

    Chapter  Google Scholar 

  5. Gennari C, Martini G, Nuti R. Secondary osteoporosis. Aging (Milano) 1998;10:214–224.

    CAS  Google Scholar 

  6. Goldring SR. Osteoporosis associated with rheumatologic disorders. In: Marcus R, Feldman D, Kelsey J (eds.). Osteoporosis (volume II). Academic Press, New York, 2001, pp. 351–362.

    Chapter  Google Scholar 

  7. Leong GM, Centor JR, Henderson NK, Eisman JA. Glucocorticoid-induced osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds.). Osteoporosis (volume II). Academic Press, New York, 2001, pp. 169–193.

    Google Scholar 

  8. Budavari S, O’Neil MJ, Smith A, Heckelman PE, Kinneart JF. The Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals (12th ed.). Merck Professional Handbook, Whitehouse Station, NJ, 1996.

    Google Scholar 

  9. Beers MH, Berkow R. Nutrition: general consideration. In: Beers MH, Berkow R (eds.). The Merck Manual of Diagnosis and Therapy. Merck Research Laboratory, Whitehouse Station, NJ, 1999, pp. 1–23.

    Google Scholar 

  10. Beers MH, Berkow R. Factors affecting drug response. In: Beers MH, Berkow R (eds.). The Merck Manual of Diagnosis and Therapy. Merck Research Laboratory, Whitehouse Station, NJ, 1999, pp. 2574–2587.

    Google Scholar 

  11. Becker KL. Principals and Practice of Endocrinology and Metabolism (3rd ed.). Lippincott Williams & Wilkins, Philadelphia, PA, 2001.

    Google Scholar 

  12. Bowman BA, Russell RM. Present Knowledge in Nutrition (8th ed.). ILSI, Washington, DC, 2001.

    Google Scholar 

  13. Committee on Nutrition Services for Medicare Beneficiaries. Nutrition support. In: Institute of Medicine Committee on Nutrition Services for Medicare Beneficiaries (ed.). The Role of Nutrition in Maintaining Health in the Nation’s Elderly. National Academy Press, Washington, DC, 2002, pp. 173–212.

    Google Scholar 

  14. Alonso-Aperte E, Varela-Moreiras G. Drugs-nutrient interactions: a potential problem during adolescence. Eur J Clin Nutr 2000;54(Suppl 1):S69-S74.

    Article  Google Scholar 

  15. Berg MJ, Rivey MP, Vern BA, Fischer LJ, Schottelius DD. Phenytoin and folic acid: individualized drug-drug interaction. Ther Drug Monit 1983;5:395–399.

    Article  PubMed  CAS  Google Scholar 

  16. Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol 2000;18:1780–1799.

    PubMed  CAS  Google Scholar 

  17. Brown RO, Dickerson RN. Drug-nutrient interactions. Am J Manag Care 1999;5:345–352.

    PubMed  CAS  Google Scholar 

  18. Gauthier I, Malone M, Lesar TS, Aronovitch S. Comparison of programs for preventing drug-nutrient interactions in hospitalized patients. Am J Health Syst Pharm 1997;54:405–411.

    PubMed  CAS  Google Scholar 

  19. Maka DA, Murphy LK. Drug-nutrient interactions: a review. AACN Clin Issues 2000;11:580–589.

    Article  PubMed  CAS  Google Scholar 

  20. Murray JJ, Healy MD. Drug-mineral interactions: a new responsibility for the hospital dietitian. J Am Diet Assoc 1991;91:66–70, 73.

    PubMed  CAS  Google Scholar 

  21. Roe DA. Drug and Nutrient Interaction (5th ed.). The American Dietetic Association, 1994.

    Google Scholar 

  22. Thomas JA. Drug-nutrient interactions. Nutr Rev 1995;53:271–282.

    Article  PubMed  CAS  Google Scholar 

  23. Thomas JA, Burns RA. Important drug-nutrient interactions in the elderly. Drugs Aging 1998;13: 199–209.

    Article  PubMed  CAS  Google Scholar 

  24. Trovato A, Nuhlicek DN, Midtling JE. Drug-nutrient interactions. Am Fam Physician 1991;44: 1651–1658.

    PubMed  CAS  Google Scholar 

  25. Utermolen V. Diet, nutrition, and drug interactions. In: Shils ME, Olson JA, Shine M, Ross AC (eds.). Modern Nutrition in Health and Disease. Lippincott Williams & Wilkins, New York, 1999, pp. 1619–1641.

    Google Scholar 

  26. Parker P. Impact of nutritional status on immune integrity. In: Gershwin ME, German JB, Keen CL (eds.). Nutrition and Immunology Principals and Practice. Humana, Totowa, NJ, 2000, pp. 147–156.

    Google Scholar 

  27. Vellas BJ, Garry PJ. Aging. In: Bowman BA, Russell RM (eds.). Present Knowledge in Nutrition. ILSI, Washington, DC, 2001, pp. 439–446.

    Google Scholar 

  28. Meskin MS. Type 2 diabetes mellitus in the elderly. Nutr M D 2000;26:4.

    Google Scholar 

  29. Beisel WR. AIDS. In: Gershwin ME, German JB, Keen CL (eds.). Nutrition and Immunology Principals and Practice. Humana, Totowa, NJ, 2000, pp. 389–401.

    Google Scholar 

  30. Gerrior J, Wanke C. Nutrition and immunodeficiency syndromes. In: Coulston AM, Rock CL, Monsen ER (eds.). Nutrition in the Prevention and Treatment of Disease. Academic, New York, 2001, pp. 741–750.

    Chapter  Google Scholar 

  31. Cunningham-Rundles S. Trace element and mineral nutrition in HIV infection and AIDS: implications for host defense. In: Bogden JD, Klevay LM (eds.). Clinical Nutrition of the Essential Trace Elements and Minerals. Humana, Totowa, NJ, 2000, pp. 333–351.

    Google Scholar 

  32. Beers MH, Berkow R. Human immunodeficiency virus infection. In: Beers MH, Berkow R (eds.). The Merck Manual of Diagnosis and Therapy. Merck Research Laboratory, Whitehouse Station, NJ, 1999, pp. 1312–1323.

    Google Scholar 

  33. Sinclair AJ, Barnett AH, Lunec J. Free radicals and antioxidant systems in health and disease. Br J Hosp Med 1990;43:334–344.

    PubMed  CAS  Google Scholar 

  34. Sifton DW. Physicians’ Desk Reference (55th ed.). Medical Economics Company, Inc., Montvale, NJ, 2001.

    Google Scholar 

  35. Baum C, Moxon D, Scott M. Gastrointestinal disease. In: Bowman BA, Russell RM (eds.). Present Knowledge in Nutrition. ILSI, Washington, DC, 2001, pp. 472–482.

    Google Scholar 

  36. Krensky AM, Storm TB, Bluestone JA. Immunomodulators: immunosuppressive agents, tolerogens, and immunomodulators. In: Hardman JG, Limbird LE, Gilman AG (eds.). The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 2001, pp. 1463–1484.

    Google Scholar 

  37. Migueles SA, Tuazon CU. Endocrine disorders in human immunodeficiency virus infection. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins, Philadelphia, PA, 2001, pp. 1947–1958.

    Google Scholar 

  38. Kupka R, Fawzi W. Zinc nutrition and HIV infection. Nutr Rev 2002;60:69–79.

    Article  PubMed  Google Scholar 

  39. Tang AM, Graham NM, Chandra RK, Saah AJ. Low serum vitamin B-12 concentrations are associated with faster human immunodeficiency virus type 1 (HIV-1) disease progression. J Nutr 1997;127:345–351.

    PubMed  CAS  Google Scholar 

  40. Beers MH, Berkow R. Disorders of carbohydrate metabolism. In: Beers MH, Berkow R (eds.). The Merck Manual of Diagnosis and Therapy. Merck Research Laboratory, Whitehouse Station, NJ, 1999, pp. 165–177.

    Google Scholar 

  41. Yoon JW, Jun HS. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. Ann N Y Acad Sci 2001; 928:200–211.

    Article  PubMed  CAS  Google Scholar 

  42. Catanese VM, Kahn CR. Secondary form of diabetes mellitus. In: Becker KL (ed.). Principals and Practice of Endocrinology and Metabolism. . Lippincott Williams & Wilkins, Philadelphia, PA, 2001, pp. 1327–1336.

    Google Scholar 

  43. Feldman EL, Stevens MJ, Russell JW, Greene DA. Diabetes neuropathy. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins, New York, 2001, pp. 1391–1399.

    Google Scholar 

  44. Kahn CR. Etiology and pathogenesis of type 2 diabetes mellitus and related disorders. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins, Philadelphia, PA, 2001, pp. 1315–1319.

    Google Scholar 

  45. Kahn CR. Glucose homeostasis and insulin action. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &amp Wilkins, New York, 2001, pp. 1303–1307.

    Google Scholar 

  46. Krolewski AS, Warram JH. Natural history of diabetes mellitus. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins, New York, 2001, pp. 1320–1327.

    Google Scholar 

  47. Duncan BB, Schmidt MI. Chronic activation of the innate immune system may underlie the metabolic syndrome. Sao Paulo Med J 2001;119:122–127.

    Article  PubMed  CAS  Google Scholar 

  48. Vozarova B, Weyer C, Lindsay RS, Pratley RE, Bogardus C, Tataranni PA. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:455–461.

    Article  PubMed  CAS  Google Scholar 

  49. Eizirik DL, Mandrup-Poulsen T. A choice of death-the signal-transduction of immune-mediated betacell apoptosis. Diabetologia 2001;44:2115–2133.

    Article  PubMed  CAS  Google Scholar 

  50. Eliopoulos GM. Diabetes and infection. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &ampWilkins, New York, 2001, pp. 1424–1428.

    Google Scholar 

  51. Preuss HG. Effects of glucose/insulin perturbations on aging and chronic disorders of aging: the evidence. J Am Coll Nutr 1997;16:397–403.

    PubMed  CAS  Google Scholar 

  52. Hehenberger K, King GL. Cardiovascular complications of diabetes mellitus. In: Becker KL (ed). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &. Wilkins, New York, 2001, pp. 1380–1391.

    Google Scholar 

  53. Strain JJ. Disturbances of micronutrient and antioxidant status in diabetes. Proc Nutr Soc 1991;50: 591–604.

    Article  PubMed  CAS  Google Scholar 

  54. Devaraj S, Jialal I. Oxidative stress and antioxidants in type 2 diabetes. In: Bendich A, Deckelbaum RJ (eds.). Primary and Secondary Preventive Nutrition. Humana, Totowa, NJ, 2001, pp. 117–125.

    Chapter  Google Scholar 

  55. Kukreja A, Cost G, Marker J, et al. Multiple immunoregulatory defects in type 1 diabetes. J Clin Invest 2002;109:131–140.

    PubMed  CAS  Google Scholar 

  56. Nolsoe RL, Kristiansen OP, Larsen ZM, Johannesen J, Pociot F, Mandrup-Poulsen T. Complete mutation scan of the human Fas ligand gene: linkage studies in Type I diabetes mellitus families. Diabetologia 2002;45:134–139.

    Article  PubMed  CAS  Google Scholar 

  57. Jain SK, McVie R, Jaramillo JJ, Palmer M, Smith T. Effect of modest vitamin E supplementation on blood glycated hemoglobin and triglyceride levels and red cell indices in type I diabetic patients. J Am Coll Nutr 1996;15:458–461.

    PubMed  CAS  Google Scholar 

  58. Kyurkchiev S, Ivanov G, Manolova V. Advanced glycosylated end products activate the functions of cell adhesion molecules on lymphoid cells. Cell Mol Life Sci 1997;53:911–916.

    Article  PubMed  CAS  Google Scholar 

  59. Lee KU. Oxidative stress markers in Korean subjects with insulin resistance syndrome. Diabetes Res Clin Pract 2001;54(Suppl 2):S29-S33.

    Article  Google Scholar 

  60. Gale EA. The discovery of type 1 diabetes. Diabetes 2001;50:217–226.

    Article  PubMed  CAS  Google Scholar 

  61. Erbagci AB, Tarakcioglu M, Coskun Y, Sivasli E, Sibel NE. Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children. Clin Biochem 2001;34:645–650.

    Article  PubMed  CAS  Google Scholar 

  62. Cornish J, Callon KE, Reid IR. Insulin increases histomorphometric indices of bone formation in vivo. Calcif Tissue Int 1996;59:492–495.

    PubMed  CAS  Google Scholar 

  63. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359:1841–1850.

    Article  PubMed  Google Scholar 

  64. Albright A. Nutrition management for type I diabetes. In: Coulston AM, Rock CL, Monsen ER (eds.). Nutrition in the Prevention and Treatment of Disease. Academic, New York, 2001, pp. 429–440.

    Chapter  Google Scholar 

  65. Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. In: Hardman JG, Limbird LE, Gilman AG (eds.). The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 2001, pp. 1679–1714.

    Google Scholar 

  66. Weir GC. Insulin therapy and its complications. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &. Wilkins, New York, 2001, pp. 1348–1360.

    Google Scholar 

  67. Liu S, Manson JE, Buring JE, Stampfer MJ, Willett WC, Ridker PM. Relation between a diet with a high glycemic load and plasma concentrations of high-sensitivity C-reactive protein in middle-aged women. Am J Clin Nutr 2002;75:492–498.

    PubMed  CAS  Google Scholar 

  68. Frier HI, Greene HL. Obesity and chronic disease impact of weight reduction. In: Bendich A, Deckelbaum RJ (eds.). Primary and Secondary Preventive Nutrition. Humana, Totowa, NJ, 2001, pp. 205–221.

    Chapter  Google Scholar 

  69. Baldeon ME, Gaskins HR. Diabetes and immunity. In: Gershwin ME, German JB, Keen CL (eds.). Nutrition and Immunology Principles and Practice.Humana, Totowa, NJ, 2000, pp. 301–311.

    Google Scholar 

  70. de Luis DA, Fernandez N, Arranz M, Aller R, Izaola O. Total homocysteine and cognitive deterioration in people with type 2 diabetes. Diabetes Res Clin Pract 2002;55:185–190.

    Article  PubMed  Google Scholar 

  71. Defronao RH. Diabetic nephropathy. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &. Wilkins, New York, 2001, pp. 1403–1418.

    Google Scholar 

  72. Eliopoulos GM. The diabetic foot. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &. Wilkins, New York, 2001, pp. 1434–1438.

    Google Scholar 

  73. Mironova MA, Klein RL, Virella GT, Lopes-Virella MF. Anti-modified LDL antibodies, LDL-containing immune complexes, and susceptibility of LDL to in vitro oxidation in patients with type 2 diabetes. Diabetes 2000;49:1033–1041.

    Article  PubMed  CAS  Google Scholar 

  74. Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, Kuller LH, Trucco M. Evidence of islet cell autoimmunity in elderly patients with type 2 diabetes. Diabetes 2000;49:32–38.

    Article  PubMed  CAS  Google Scholar 

  75. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult.): definition, characterization, and potential prevention. Diabetes Care 2001;24:1460–1467.

    Article  PubMed  CAS  Google Scholar 

  76. Rand LI. Diabetes and the eye. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &. Wilkins, New York, 2001, pp. 1418–1424.

    Google Scholar 

  77. Ternand C. A changing diet for patients with diabetes. Nutr M D 2000;27:6.

    Google Scholar 

  78. Hendler SS, Rorvik D. Physicians’ Desk Reference for Nutritional Supplements. Medical Economics Company, Inc., Montvale, NJ, 2001.

    Google Scholar 

  79. Goldfine AB, Maratos-Flier E. Oral agents for the treatment of type 2 diabetes mellitus. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &. Wilkins, Philadelphia, PA, 2001, pp. 1344–1348.

    Google Scholar 

  80. Moller DE. New drug targets for type 2 diabetes and the metabolic syndrome. Nature 2001;414:821–827.

    Article  PubMed  CAS  Google Scholar 

  81. Gordon FD, Falchuk KR. Gastrointestinal complications of diabetes. In: Becker KL(ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams & Wilkins, New York, 2001, pp. 1399–1403.

    Google Scholar 

  82. Buysschaert M, Bobbioni E, Starkie M, Frith L. Troglitazone in combination with sulphonylurea improves glycaemic control in type 2 diabetic patients inadequately controlled by sulphonylurea therapy alone. Troglitazone Study Group. Diabet Med 1999;16:147–153.

    Article  PubMed  CAS  Google Scholar 

  83. Cohen JA, Jeffers BW, Stabler S, Schrier RW, Estascio R. Increasing homocysteine levels and diabetic autonomic neuropathy. Auton Neurosci 2001;87:268–273.

    Article  PubMed  CAS  Google Scholar 

  84. Ambrosch A, Dierkes J, Lobmann R, et al. Relation between homocysteinaemia and diabetic neuropathy in patients with Type 2 diabetes mellitus. Diabet Med 2001;18:185–192.

    Article  PubMed  CAS  Google Scholar 

  85. Blom HJ. Diseases and drugs associated with hyperhomocysteinemia. In: Carmel R, Jacobsen DW (eds.). Homocysteine in Health and Disease. Cambridge University Press, New York, 2001, pp. 331–340.

    Google Scholar 

  86. Hovind P, Tarnow L, Rossing P, et al. Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1. Am J Kidney Dis 2001;38:1376–1380.

    Article  PubMed  CAS  Google Scholar 

  87. Mutus B, Rabini RA, Staffolani R, et al. Homocysteine-induced inhibition of nitric oxide production in platelets: a study on healthy and diabetic subjects. Diabetologia 2001;44:979–982.

    Article  PubMed  CAS  Google Scholar 

  88. Scaglione L, Gambino R, Rolfo E, et al. Plasma homocysteine, methylenetetrahydrofolate reductase gene polymorphism and carotid intima-media thickness in Italian type 2 diabetic patients. Eur J Clin Invest 2002;32:24–28.

    Article  PubMed  CAS  Google Scholar 

  89. Hoogeveen EK, Rothman KJ. Hyperhomocysteinemia, diabetes, and cardiovascular disease. In: Bendich A, Deckelbaum RJ (eds.). Primary and Secondary Preventive Nutrition. Humana, Totowa, NJ, 2001, 127–154.

    Chapter  Google Scholar 

  90. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40: 405–412.

    Article  PubMed  CAS  Google Scholar 

  91. Nath N, Chari SN, Rathi AB. Superoxide dismutase in diabetic polymorphonuclear leukocytes. Diabetes 1984;33:586–589.

    Article  PubMed  CAS  Google Scholar 

  92. Preuss HG. The insulin system: influence of antioxidants. J Am Coll Nutr 1998;17:101–102.

    PubMed  CAS  Google Scholar 

  93. Paolisso G, D’Amore A, Galzerano D, et al. Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type II diabetic patients. Diabetes Care 1993;16:1433–1437.

    Article  PubMed  CAS  Google Scholar 

  94. Ceriello A, Giugliano D, Quatraro A, Donzella C, Dipalo G, Lefebvre PJ. Vitamin E reduction of protein glycosylation in diabetes. New prospect for prevention of diabetic complications? Diabetes Care 1991;14:68–72.

    Article  PubMed  CAS  Google Scholar 

  95. Anderson RA. Nutritional factors influencing the glucose/insulin system: chromium. J Am Coll Nutr 1997;16:404–410.

    PubMed  CAS  Google Scholar 

  96. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997;46:1786–1791.

    Article  PubMed  CAS  Google Scholar 

  97. Beers MH, Berkow R. Diffuse connective tissue disease. In: Beers MH, Berkow R (eds.). The Merck Manual of Diagnosis and Therapy. Merck Research Laboratory, Whitehouse Station, NJ, 1999, pp. 416–423.

    Google Scholar 

  98. Mongey AB, Hess EV. Drug and environmental effects on the induction of autoimmunity. J Lab Clin Med 1993;122:652–657.

    PubMed  CAS  Google Scholar 

  99. Newkirk MM, LePage K, Niwa T, Rubin L. Advanced glycation endproducts (AGE) on IgG, a target for circulating antibodies in North American Indians with rheumatoid arthritis (RA). Cell Mol Biol (Noisy-le-grand) 1998;44:1129–1138.

    CAS  Google Scholar 

  100. Meyer O. Atherosclerosis and connective tissue diseases. Joint Bone Spine 2001;68:564–575.

    Article  PubMed  CAS  Google Scholar 

  101. Langford CA, Klippel JH, Balow JE, James SP, Sneller MC., Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 2: inflammatory bowel disease, systemic vasculitis, and therapeutic toxicity. Ann Intern Med 1998;129:49–58.

    PubMed  CAS  Google Scholar 

  102. Balint G, Gergely P Jr. Clinical immunotoxicity of antirheumatic drugs. Inflamm Res 1996;45(Suppl 2):S91-S95.

    Google Scholar 

  103. Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, Sanchez-Andrade A, Gonzalez-Gay MA. Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases. Br J Rheumatol 1997;36:1095–1099.

    Article  PubMed  CAS  Google Scholar 

  104. Axelrod L. Corticosteroid therapy. In: Becker KL (ed.). Principles and Practice of Endocrinology and Metabolism. Lippincott Williams &. Wilkins, Philadelphia, PA, 2001, pp. 751–772.

    Google Scholar 

  105. Langford CA, Klippel JH, Balow JE, James SP, Sneller MC. Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 1: rheumatologic and renal diseases. Ann Intern Med 1998;128:1021–1028.

    PubMed  CAS  Google Scholar 

  106. Morgan SL, Baggott JE. Role of dietary folate and oral folate supplements in the prevention of drug toxicity during anifolate therapy for nonneoplastic disease. In: Bendich A, Butterworth CE Jr (eds.). Micronutrients in Health and in Disease Prevention. Marcel Dekker, Inc., New York, 1991, pp. 333–358.

    Google Scholar 

  107. Rozin A, Schapira D, Braun-Moscovici Y, Nahir AM. Cotrimoxazole treatment for rheumatoid arthritis. Semin Arthritis Rheum 2001;31:133–141.

    Article  PubMed  CAS  Google Scholar 

  108. Rozin A, Schapira D, Braun-Moscovici Y, Nahir AM. Cotrimoxazole treatment for rheumatoid arthritis. Semin Arthritis Rheum 2001;31:133–141.: http://www.enbrel.com. 2002.

    Article  PubMed  CAS  Google Scholar 

  109. Chan LN. Drug-nutrient interactions in transplant recipients. J Parenter Enteral Nutr 2001;25: 132–141.

    Article  CAS  Google Scholar 

  110. de Sousa M. Circulation and distribution of iron: a key to immune interaction. In: Cunningham-Rundles S (ed.). Nutrient Modulation of the Immune Response, Marcel Dekker, Inc., New York, 1993.

    Google Scholar 

  111. Galperin C, Fernandes G, Oliveira RM, Gershwin ME. Nutritional modulation of autoimmune diseases. In: Gershwin ME, German JB, Keen CL (eds.). Nutrition and Immunology Principles and Practice. Humana, Totowa, NJ, 2000, pp. 313–328.

    Google Scholar 

  112. Belluzzi A. Polyunsaturated fatty acids and autoimmune diseases. In: Bendich A, Deckelbaum RJ (eds.). Primary and Secondary Preventive Nutrition. Humana, Totowa, NJ, 2001, pp. 271–287.

    Chapter  Google Scholar 

  113. Grodstein F, Colditz GA, Stampfer MJ. Post-menopausal hormone use and tooth loss: a prospective study. J Am Dent Assoc 1996;127:370–377.

    PubMed  CAS  Google Scholar 

  114. Marcus R, Feldman D, Kelsey J. Osteoporosis (volume I) (2nd ed.). Academic, New York, 2001.

    Google Scholar 

  115. Marcus R, Feldman D, Kelsey J. Osteoporosis (volume II) (2nd ed.). Academic, New York, 2001.

    Google Scholar 

  116. Heaney RP. Osteoporosis: mineral, vitamins, and other micronutrients. In: Bendich A, Deckelbaum RJ (eds.). Preventive Nutrition: The Comprehensive Guide for Health Professionals. Humana, Totowa, NJ, 2001, pp. 271–292.

    Google Scholar 

  117. Orwoll ES. The prevention and therapy of osteoporsis in men. In: Orwoll ES (ed.). Osteoporosis in Men: The Effects of Gender on Skeletal Health. Academic, New York, 1999, pp. 553–569.

    Google Scholar 

  118. Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997;32:1247–1255.

    Article  PubMed  CAS  Google Scholar 

  119. Ebeling PR. Secondary causes of osteoporosis in men. In: Orwoll ES (ed.). Osteoporosis in Men: The Effects of Gender on Skeletal Health. Academic, New York, 1999, pp. 483–514.

    Google Scholar 

  120. Heller HJ, Sakhaee K. Anticonvulsant-induced bone disease: a plea for monitoring and treatment. Arch Neurol 2001;58:1352–1353.

    Article  PubMed  CAS  Google Scholar 

  121. Jamal SA, Browner WS, Bauer DC, Cummings SR. Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998;128:829–832.

    PubMed  CAS  Google Scholar 

  122. Kaye PS. Osteoporosis and fracture as a result of gastrointestinal and hepatic disorders. Practical Gastroenterol 2002;15–28.

    Google Scholar 

  123. Valmadrid C, Voorhees C, Litt B, Schneyer CR. Practice patterns of neurologists regarding bone and mineral effects of antiepileptic drug therapy. Arch Neurol 2001;58:1369–1374.

    Article  PubMed  CAS  Google Scholar 

  124. Lappe JM, Tinley ST. Prevention of osteoporosis in women treated for hereditary breast and ovarian carcinoma: a need that is overlooked. Cancer 1998;83:830–834.

    Article  PubMed  CAS  Google Scholar 

  125. Hertz M, Juji T, Tanaka SMS. A therapeutic RANKL vaccine induces neutralizing anti-RANKL antibodies and prevents bone loss in overiectomized mice. J Bone Miner Res 2001;16:S222.

    Google Scholar 

  126. Marcus R. Use of estrogen for the prevention and treatment of osteoporosis. In: Rosen CJ (ed.). Osteoporosis: Diagnostic and Therapeutic Principles. Humana, Totowa, NJ, 1996, 159–172.

    Google Scholar 

  127. Khosla S, Riggs BL. Treatment options for osteoporosis. Mayo Clin Proc 1995;70:978–982.

    Article  PubMed  CAS  Google Scholar 

  128. Guyatt GH. An introduction to clinical decision making in osteoporosis. In: Rosen CJ (ed.). Osteoporosis: Diagnostic and Therapeutic Principles. Humana, Totowa, NJ, 1996, pp. 145–149.

    Google Scholar 

  129. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002;288:321–333.

    Google Scholar 

  130. Fleisch H. Basic biology of bisphosphonates. In: Marcus R, Feldman D, Kelsey J (eds.). Osteoporosis (volume I). Academic, New York, 2001, pp. 449–467.

    Chapter  Google Scholar 

  131. Marcus R. Agents affecting calcification and bone turnover. In: Hardman JG, Limbird LE, Gilman AG (eds.). The Pharmacological Basis of Therapeutics. McGraw-Hill, New York, 2001, pp. 1715–1743.

    Google Scholar 

  132. Colman E, Hedin R, Swann J, Orloff D. A brief history of calcitonin. Lancet 2002;359:885–886.

    Article  PubMed  Google Scholar 

  133. Hoff AO, Cote GJ, Gagel RF. Calcitonin. In: Marcus R, Feldman D, Kelsey J (eds.). Osteoporosis (volume I). Academic, New York, 2001, pp. 247–255.

    Chapter  Google Scholar 

  134. Gallagher JC, Fowler SE, Detter JR, Sherman SS. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss. J Clin Endocrinol Metab 2001;86:3618–3628.

    Article  PubMed  CAS  Google Scholar 

  135. Bilezikian JP, Silverberg SJ. The role of parathyroid hormone and vitamin D in the pathogenesis of osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds.). Osteoporosis (volume II). Academic, New York, 2001, pp. 71–84.

    Chapter  Google Scholar 

  136. Nissenson RA. Parathyroid hormone and parathyroid hormone-related protein. In: Marcus R, Feldman D, Kelsey J (eds.). Osteoporosis (volume I). Academic, New York, 2001, pp. 221–246.

    Chapter  Google Scholar 

  137. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. Am J Med 2000;108:153–164.

    Article  PubMed  CAS  Google Scholar 

  138. Cassidy JT, Hillman LS. Abnormalities in skeletal growth in children with juvenile rheumatoid arthritis. Rheum Dis Clin N Am 1997;23:499–522.

    Article  CAS  Google Scholar 

  139. Pollak RD, Karmeli F, Eliakim R, Ackerman Z, Tabb K, Rachmilewitz D. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998;93:1483–1490.

    Article  PubMed  CAS  Google Scholar 

  140. Reid IR. Glucocorticoids and osteoporosis. In: Orwoll ES (ed.). Osteoporosis in Men: The Effects of Gender on Skeletal Health. Academic, New York, 1999, pp. 417–436.

    Google Scholar 

  141. Reid IR. Glucocorticoid-induced osteoporosis. Baillieres Best Pract Res Clin Endocrinol Metab 2000;14:279–298.

    Article  PubMed  CAS  Google Scholar 

  142. Silverberg MS, Steinhart AH. Bone density in inflammatory bowel disease. Clin Pers Gastroenterol 2000;117–124.

    Google Scholar 

  143. Stempfle HU, Werner C, Siebert U, et al. The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. Transplantation 2002;73:547–552.

    Article  PubMed  CAS  Google Scholar 

  144. Marcus R. Calcium as a primary treatment and prevention modality for osteoporosis. In: Rosen CJ (ed.). Osteoporosis: Diagnostic and Therapeutic Principles. Humana, Totowa, NJ, 1996, pp. 151–158.

    Google Scholar 

  145. Reid IR, Ames RW, Evans MC, Gamble GD, Sharpe SJ. Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: a randomized controlled trial. Am J Med 1995;98:331–335.

    Article  PubMed  CAS  Google Scholar 

  146. Stock JL. Drug therapy. In: Rosen CJ, ed. Osteoporosis: Diagnostic and Therapeutic Principles. Humana, Totowa, NJ, 1996, pp. 173–187.

    Google Scholar 

  147. Nieves JW, Komar L, Cosman F, Lindsay R. Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis. Am J Clin Nutr 1998;67:18–24.

    PubMed  CAS  Google Scholar 

  148. Coulston AM. Nutritional management for type 2 diabetes. In: Coulston AM, Rock CL, Monsen ER (eds.). Nutrition in the Prevention and Treatment of Disease. Academic, New York, 2001, pp. 441–452.

    Chapter  Google Scholar 

Download references

Authors
  1. Adrianne Bendich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronit Zilberboim
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Nutrition Division, Institute of Food Research, Norwich Research Park, Norfolk, UK

    David A. Hughes PhD, RNutr

  2. Epsom and St. Helier University Hospitals NHS Trust, Surrey, UK

    L. Gail Darlington MD, FRCP

  3. GlaxoSmithKline Consumer Healthcare, Parsippany, NJ, USA

    Adrianne Bendich PhD, FACN

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bendich, A., Zilberboim, R. (2004). Use of Drugs that Affect Nutrition and Immune Function. In: Hughes, D.A., Darlington, L.G., Bendich, A. (eds) Diet and Human Immune Function. Nutrition and Health. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-652-2_22

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-652-2_22

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-422-7

  • Online ISBN: 978-1-59259-652-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation